Puration Kali and Nouveau Announce Healthcare Industry Veteran Steven Rash as CEO of US Cannabis Health JV
November 23 2018 - 9:21AM
InvestorsHub NewsWire
Dallas, TX -- November 23, 2018 --
InvestorsHub NewsWire -- Puration, Inc. (USOTC:
PURA) (“PURA”) with Kail, Inc. (USOTC:
KALY) (“KALY”) and Nouveau Health Pharmaceuticals, Inc.
(USOTC:
NOUV) (“NOUV”) today announced appointed Steven Rash as CEO of
the US Cannabis Health LLC. The
three companies have each contributed assets in exchange for
respective 30% stakes in US Cannabis Health which has been set up
to develop cannabis pharmaceutical and wellness therapies estimated
to be a $50 Billion market by
2029.
An online
presentation was recently
released detailing the contributions of each of the three
corporations to US Cannabis Health in addition to providing an
overview of the JV’s business plan.
Steven Rash is both a healthcare
industry veteran and cannabis industry veteran. Mr. Rash is a
founder and current CEO of North American Cannabis Holdings,
(USOTC:
USMJ) (“USMJ”). Mr. Rash is a
medical industry veteran with a lengthy list of career
accomplishments and experiences. He has negotiated medical
device licensing agreements and health care partner strategic
alliances that combined have generated over $650 million in new
revenues. Mr. Rash has also managed numerous drug trials and
secured multiple FDA approvals. He has signed over 400
managed care contracts and made more than 200 Boardroom
presentations at Fortune 500 companies. Mr. Rash served as
President and CEO of American BioMed, Vice President of Blue Rhino
Corporation and Division President of Maxum Health Corporation. He
earlier held numerous Vice President positions at BOC Group, PLC.
Mr. Rash has a BS in Business Administration from the University of
Delaware and an MBA from Southern Illinois University. Mr.
Rash is also a Veteran of the United States
Army.
Recent analyst research coverage published after
PURA’s announcement disclosing its participation in US Cannabis
Health reflects a positive overall outlook on the company’s
prospects heading into 2019 with a speculative “Buy” rating and a
$0.25 Target PPS.
Learn
more about Puration at https://www.purationinc.com/
This press release contains
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended (the "Exchange Act"),
and as such, may involve risks and uncertainties. These forward
looking statements relate to, amongst other things, current
expectation of the business environment in which the company
operates, potential future performance, projections of future
performance and the perceived opportunities in the market. The
company's actual performance, results and achievements may differ
materially from the expressed or implied in such forward-looking
statements as a result of a wide range of
factors.
Puration,
Inc.
Brian Shibley,
info@aciconglomerated.com
(800) 861-1350
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Nouveau Life Pharmaceuti... (PK) (USOTC:NOUV)
Historical Stock Chart
From Sep 2023 to Sep 2024